Clinical Trial Update: Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating conditioning with alemtuzumab, busulfan, and cyclophosphamide followed by donor stem cell transplantation in hematologic can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• BUSULFAN (Busulfan)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Graft Versus Host Disease, Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-05-24